Helen C. Kales, MD, presented the keynote address at the 2023 Dr. Daniel I. Kaufer Lecture Series, an endowed educational program devoted to shaping future generations of dementia care professionals.
News
UW–Madison Alzheimer’s disease experts participate in dementia friendly events at the Wisconsin Executive Residence
On June 8, 2023, Wisconsin Governor Tony Evers and First Lady Kathy Evers welcomed people living with dementia and their caregivers, and representatives from community organizations, to dementia friendly events at the Wisconsin Executive Residence. …
Shamrock Shuffle ‘23 raised over $16K for Alzheimer’s research
On March 11, the Anchor Bay Bar and Grill in Wisconsin Rapids, WI, hosted its 2023 Shamrock Shuffle raising over $16,000 for the UW Initiative to End Alzheimer’s.
Dr. Nathaniel Chin Featured in UW SMPH ‘Quarterly’ Magazine
Nathaniel Chin, MD, was featured in the latest issue of Quarterly magazine. In the article “How Grief Transformed Me,” Chin discusses how learning of his father’s Alzheimer’s disease diagnosis altered his professional trajectory.
Pedaling to preserve memories down under with Dave and French Fry
Dave Adam continues to be a champion for Alzheimer’s disease research. Dave is a Wisconsin man who cycled across Canada last year to help raise funds for Alzheimer’s disease programs at UW–Madison. This year he’s going down under to Australia and plans to bike 2,500 miles to support the UW Initiative to End Alzheimer’s.
Announcing the IEA Innovation Fund
The UW Initiative to End Alzheimer’s (IEA) is pleased to announce the IEA Innovation Fund, providing project support for researchers from the Wisconsin Alzheimer’s Disease Research Center (ADRC) or Wisconsin Alzheimer’s Institute (WAI). The IEA Innovation Fund will help advance the University of Wisconsin–Madison’s Alzheimer’s disease researchers’ most promising ideas by providing an open door to funding opportunities that foster translational, innovative and inclusive advancements in Alzheimer’s disease research.
A closer look at lecanemab
In January, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway to treat Alzheimer’s disease. Nathaniel Chin, MD, recently interviewed Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to inform people about the research behind the new Alzheimer’s treatment, the drug’s benefits and risks, and more.
UW study focuses on Alzheimer’s disease treatment and prevention in the Black community
Carey Gleason, PhD, MS, and her research team’s African Americans Fighting Alzheimer’s in Midlife (AA-FAIM) study is entering its second, five-year cycle and they are focused on making Alzheimer’s research more inclusive.
Dr. Maria Mora Pinzon appointed to assistant professor
Maria Mora Pinzon, MD, MS, FACPM, was recently appointed to assistant professor on the tenure track in the Division of Geriatrics and Gerontology at the University of Wisconsin School of Medicine and Public Health, where she will continue working with the Wisconsin Alzheimer’s Institute and expand her research program.
Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval
On the latest episode of the podcast, Dementia Matters, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials.